Domestic new crown therapy drug price disclosure: 1 Kandawei's single remoteness is less than 10,000 yuan

Domestic new crown therapy drug price disclosure!

On July 11, the Gansu Provincial Public Resources Trading Center issued a notice saying that the "New Crown Epidemic Prevention and Control Drugs" Anbawei's anti -anti -anti -anti -anti -anti -injection radiation fluid has been emergency network.

The combination of Antimoto/Romi Siwei's anti -injections is the new crown treatment of Teng Shengbo's subsidiary Teng Shenghua. On July 8th, this neutralized antibody was officially launched in China.

At the launch conference, Luo Yongqing, the president of Tengshengbo Pharmaceutical and General Manager of Greater China, and CEO of Teng Shenghua, revealed the price of the drug: The pricing will be lower than that of similar overseas products, and it is expected to be within 10,000 yuan. "

However, according to the information disclosed by Gansu, the unit price of the two monoclonal antibodies is "not higher than the lowest price of 2417 yuan in the country". According to Luo Yongqing's usage, the two prices are not higher than 4834 yuan, which is far lower than 10,000 yuan.

Anbawei's anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -anti -risk adult and youth new coronary virus infection patients who are approved in China for the treatment of light and ordinary types are used in China. It was included in the ninth edition of the new crown treatment plan in March this year. The procurement of the drug in Gansu Province began on July 12.

On July 12, Hong Kong stocks Tengshengbo's stock price dived. As of the closing, Tengshengbo Pharmaceutical fell 21.46%.

Writing | Nicotinamide

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

- END -